| Summary: | 碩士 === 東吳大學 === EMBA高階經營碩士在職專班 === 107 === Abstract
This research is different from the research direction of biomedical technology companies in the past, focusing on the development of biopharmaceutical technology companies with good performance in the world, and evaluating the practical application and profitability of R&D efficiency in the market. The data envelopment analysis method of Dynamic DEA model theory is used to evaluate the efficiency of the world's 27 biomedical technology companies from 2015 to 2017, including the research and development expenses, operating costs, output income, gross profit and fixed Assets are analyzed as variables to understand the performance of average annual input and output efficiency, to assess the quality of intertemporal efficiency, and to examine operating performance by ranking before and after total efficiency.
The research results show that the investment in research and development expenses is indeed efficient. The rest between the research and development expenses and the total operating income also observed that the world's 27 major biomedical technology companies are constantly investing in the research and development expenses, for these large-scale organisms. For medical technology companies, the classification and selection of drugs in the direction of R&D efficiency has been quite mature.
|
|---|
